Tramadol News and Research

RSS
Labopharm completes joint venture with Gruppo Angelini

Labopharm completes joint venture with Gruppo Angelini

FDA approves Cipher's CIP-TRAMADOL ER for chronic pain

FDA approves Cipher's CIP-TRAMADOL ER for chronic pain

Biovail reports 27% increase in first-quarter 2010 total revenues

Biovail reports 27% increase in first-quarter 2010 total revenues

Labopharm's first-quarter fiscal 2010 revenues from product sales decrease $0.4M to $3.2M

Labopharm's first-quarter fiscal 2010 revenues from product sales decrease $0.4M to $3.2M

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010

Labopharm, Gruppo Angelini sign agreement to commercialize OLEPTRO in the U.S.

Labopharm, Gruppo Angelini sign agreement to commercialize OLEPTRO in the U.S.

Cipher Pharmaceuticals' first-quarter total revenue up 52%

Cipher Pharmaceuticals' first-quarter total revenue up 52%

Labopharm launches INTELLITAB abuse and misuse-deterrent technology platform

Labopharm launches INTELLITAB abuse and misuse-deterrent technology platform

Labopharm: Investment report

Labopharm: Investment report

Nippon Shinyaku to market and sell Labopharm's once-daily tramadol in Japan

Nippon Shinyaku to market and sell Labopharm's once-daily tramadol in Japan

Cipher Pharmaceuticals' enrollment milestone in CIP-ISOTRETINOIN study triggers $2.0M milestone payment

Cipher Pharmaceuticals' enrollment milestone in CIP-ISOTRETINOIN study triggers $2.0M milestone payment

Health Canada accepts Cipher Pharmaceuticals' NDS for CIP-TRAMADOL ER

Health Canada accepts Cipher Pharmaceuticals' NDS for CIP-TRAMADOL ER

Biovail reports 33% increase in total revenues for fourth-quarter 2009

Biovail reports 33% increase in total revenues for fourth-quarter 2009

Sales revenue from Labopharm's once-daily tramadol increases to $4.7M for fourth-quarter fiscal 2009

Sales revenue from Labopharm's once-daily tramadol increases to $4.7M for fourth-quarter fiscal 2009

Par Pharmaceutical reports total revenues of $1,193.2 million for 2009

Par Pharmaceutical reports total revenues of $1,193.2 million for 2009

Diabetic Neuropathy: Drug having disease-modifying potential will earn 40% patient share in the U.S

Diabetic Neuropathy: Drug having disease-modifying potential will earn 40% patient share in the U.S

Labopharm's public offering underwriters exercise over-allotment option to purchase additional 1.7M units

Labopharm's public offering underwriters exercise over-allotment option to purchase additional 1.7M units

Labopharm closes previously announced underwritten public offering of 11,764,706 units

Labopharm closes previously announced underwritten public offering of 11,764,706 units

Cipher Pharmaceuticals announces fourth-quarter and fiscal year 2009 results

Cipher Pharmaceuticals announces fourth-quarter and fiscal year 2009 results

Labopharm prices underwritten public offering of 11.7M units

Labopharm prices underwritten public offering of 11.7M units